GLINLICE M2 Tablet is an effective oral anti-diabetic medication formulated with Metformin Hydrochloride (Prolonged Release) and Glimepiride, designed to manage Type 2 Diabetes Mellitus in adults. This dual-combination therapy works through two complementary mechanisms to improve blood glucose control.

Metformin is a biguanide that decreases hepatic glucose production, reduces intestinal absorption of glucose, and enhances insulin sensitivity in peripheral tissues. The prolonged-release formulation ensures a steady release of the medicine, resulting in better gastrointestinal tolerability and sustained glycemic control throughout the day.

Glimepiride, a sulfonylurea, stimulates the pancreas to release more insulin by acting on beta cells. It complements the action of Metformin by improving postprandial (after meal) glucose control.

Together, this combination helps in reducing fasting and post-meal blood sugar levels, improving glycemic control, and delaying diabetes-related complications such as neuropathy, nephropathy, and retinopathy. It is often prescribed as part of a comprehensive diabetes management plan that includes lifestyle changes and dietary control.